外泌体在肝细胞肝癌发展和诊断中的研究进展

doi:10.20047/j.issn1673-7210.2023.10.08

摘要
图/表
参考文献(31)
相关文章 (15)

全文: PDF (420 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要在全球范围内，肝细胞肝癌（HCC）是第三大最常见的癌症类型。大多数患者在诊断时表现为肝内或远处器官转移，其预后较差。HCC早期发病隐匿，早期诊断一直以来都是肝癌诊疗的热点研究方向之一。随着lncRNA、miRNA等在HCC中作用的逐渐明确，外泌体在肿瘤进展和诊断中的作用逐渐受到研究者的重视。近年来发现，外泌体在HCC的发生发展过程中具有重要作用，可应用于HCC的诊断和治疗。本文就外泌体在HCC进展中的作用及作为诊断HCC的肿瘤标志物的临床前研究进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周丁杰戈伟曹德东

关键词 ：肝细胞肝癌, 外泌体, 长链非编码RNA, 生物标志物, 诊断

Abstract：Globally, hepatocellular carcinoma (HCC) is the fourth most common type of cancer. Most patients present with intrahepatic or distant organ metastases at the time of diagnosis, and their prognosis is poor. The early onset of HCC is insidious, and early diagnosis has long been one of the major research areas in the treatment of liver cancer. As the role of lncRNA and miRNA in HCC has been gradually clarified, the role of exosomes in tumor progression, and diagnosis has gradually received attention from researchers. In recent years, it has been found that exosomes have an important role in the development of HCC and can be applied in the diagnosis and treatment of HCC. This paper reviews the role of exosomes in the progression of HCC, and their development as tumour markers for the diagnosis of HCC.

Key words： Hepatocellular carcinoma Exosomes Long non-coding RNA Biomarker Diagnostics

基金资助:国家自然科学基金青年科学基金资助项目（817 00208）。

通讯作者: 戈伟（1960.5-），男，博士，副主任医师；研究方向：肺癌、消化道肿瘤、淋巴瘤。

作者简介: 周丁杰（1997.11-），男，武汉大学第一临床学院2020级肿瘤学专业在读硕士研究生；研究方向：放射肿瘤学。

引用本文:

周丁杰戈伟曹德东. 外泌体在肝细胞肝癌发展和诊断中的研究进展[J]. 中国医药导报, 2023, 20(10): 42-44,54.
ZHOU Dingjie GE Wei CAO Dedong. Advances in the study of exosomes in the development and diagnosis of hepatocellular liver cancer. 中国医药导报, 2023, 20(10): 42-44,54.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.10.08 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I10/42

[1] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. 2021，71（3）：209-249.
[2] Wang H，Yu L，Huang P，et al. Tumor-associated Exosomes Are Involved in Hepatocellular Carcinoma Tumorigenesis，Diagnosis，and Treatment [J]. J Clin Transl Hepatol，2022，10（3）：496-508.
[3] Xue D，Han J，Liu Y，et al. Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma （review） [J]. Cancer Biol Ther，2021，22（4）：279-290.
[4] He C，Zheng S，Luo Y，et al. Exosome Theranostics：Biology and Translational Medicine [J]. Theranostics，2018，8（1）：237-255.
[5] Kalluri R，Lebleu VS. The biology function and biomedical applications of exosomes [J]. Science，2020，367（6478）：69- 77.
[6] Wang G，Liu W，Zou Y，et al. Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a-MET pathway [J]. EBioMedicine，2019，40：432-445.
[7] Li J，Li Z，Jiang P，et al. Circular RNA IARS （circ-IARS） secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis [J]. J Exp Clin Cancer Res，2018，37（1）：177-184.
[8] Chen X，Chi H，Zhao X，et al. Role of Exosomes in Immune Microenvironment of Hepatocellular Carcinoma [J]. J Oncol，2022，2022：2521-2525.
[9] Pascut D，Pratama MY，Vo NVT，et al. The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma：The Role of Exosomal microRNAs and their Clinical Implications [J]. Cancers，2020，12（4）：815-823.
[10] Pan JH，Zhou H，Zhao XX，et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma：Potential in diagnosis and antitumour treatments （Review） [J]. Int J Mol Med，2018，41（4）：1809-1816.
[11] Li X，Li C，Zhang L，et al. The significance of exosomes in the development and treatment of hepatocellular carcinoma [J]. Mol Cancer，2020，19（1）：1-15.
[12] Kumari N，Choi SH. Tumor-associated macrophages in cancer：recent advancements in cancer nanoimmunotherapies [J]. J Exp Clin Cancer Res，2022，41（1）：68-76.
[13] Li C，Xu X，Wei S，et al. Tumor-associated macrophages：potential therapeutic strategies and future prospects in cancer [J]. J Immunother Cancer，2021，9（1）：13-41.
[14] Valenti R，Huber V，Filipazzi P，et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes [J]. Cancer Res，2006， 66（18）：9290-9298.
[15] Conigliaro A，Costa V，Lo Dico A，et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA [J]. Mol Cancer，2015，14：155-164.
[16] Reghupaty SC，Sarkar D. Current Status of Gene Therapy in Hepatocellular Carcinoma [J]. Cancers，2019，11（9）：12-65.
[17] Zhang N，Duan WD，Leng JJ，et al. STAT3 regulates the migration and invasion of a stem-like subpopulation through microRNA-21 and multiple targets in hepatocellular carcinoma [J]. Oncol Rep，2015，33（3）：1493-1498.
[18] Sruthi TV，Edatt L，Raji GR，et al. Horizontal transfer of miR-23a from hypoxic tumor cell colonies can induce angiogenesis [J]. J Cell Physio，2018，233（4）：3498-3514.
[19] Huang Y，Hong W，Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis [J]. J Hematol Oncol，2022，15（1）：129-140.
[20] Villegas-Pineda JC，Lizarazo-Taborda MDR，Ramírez-De- Arellano A，et al. Exosomal miRNAs and lncRNAs：The Modulator Keys of Cancer-Associated Fibroblasts in the Genesis and Progression of Malignant Neoplasms [J]. Front Cell Dev Biol，2021，9：71-78.
[21] Yang B，Feng X，Liu H，et al. High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma [J]. Oncogene，2020，39（42）：6529-6543.
[22] Chen QL，Xie CF，Feng KL，et al. microRNAs carried by exosomes promote epithelial-mesenchymal transition and metastasis of liver cancer cells [J]. Am J Transl Res，2020， 12（10）：6811-6826.
[23] Tian W，Liu S，Li B. Potential Role of Exosomes in Cancer Metastasis [J]. BioMed Research International，2019，2019（4）：649-705.
[24] Zhao Y，Liu P，Tan H，et al. Exosomes as Smart Nanoplatforms for Diagnosis and Therapy of Cancer [J]. Front Oncol，2021，11（7）：431-489.
[25] Tian XP，Wang CY，Jin XH，et al. Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis [J]. Theranostics，2019，9（7）：1965-1979.
[26] Cui Y，Xu HF，Liu MY，et al. Mechanism of exosomal microRNA-224 in development of hepatocellular carcinoma and its diagnostic and prognostic value [J]. World J Gastroenterol，2019，25（15）：1890-1898.
[27] Li W，Ding X，Wang S，et al. Downregulation of serum exosomal miR-320d predicts poor prognosis in hepatocellular carcinoma [J]. Journal of clinical laboratory analysis，2020， 34（6）：32-39.
[28] Zhuang LK，Yang YT，Ma X，et al. MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST [J]. Cell Death Dis，2016，7（4）：20-32.
[29] Nakano T，Chen IH，Wang CC，et al. Circulating exosomal miR-92b：Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence [J]. Am J Transplant，2019，19（12）：250- 262.
[30] Li S，Yao J，Xie M，et al. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses [J]. J Hematol Oncol，2018，11（1）：54-76.
[31] Sugimachi K，Matsumura T，Hirata H，et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation [J]. Br J Cancer，2015，112（3）：532-538.